Literature DB >> 28848823

The 2014 Updated GOLD Strategy: A Comparison of the Various Scenarios.

Sarah Wilke1,2, Dionne E Smid1,2, Martijn A Spruit2, Daisy J A Janssen2,3, Jean W M Muris4, Thys van der Molen5, Marjan van den Akker4,6, Paul W Jones7, Emiel F M Wouters2,8, Frits M E Franssen2.   

Abstract

Background: The 2014 updated Global initiative for chronic Obstructive Lung Disease (GOLD) strategy added the St. George's Respiratory Questionnaire (SGRQ) as the fourth possible symptoms measure. The impact of the suggested tools for symptoms of COPD and the different definitions of future risk on the frequency distribution and clinical characteristics of the GOLD groups remain unknown.
Methods: Demographic and clinical characteristics were assessed in 542 patients with COPD (57.7% male, age 64.6 [9.0] years, FEV1 54.7 [22.3]% predicted). Health status was assessed by the COPD-specific SGRQ and symptoms of anxiety and depression by the Hospital Anxiety and Depression Scale, anxiety (HADS-A) and depression (HADS-D) subscale. Cohen's Kappa was used to assess agreement between groups.
Results: Level of agreement in frequency distribution using the modified Medical Research Council dyspnea (mMRC) scale ≥2, COPD Assessment Test (CAT) ≥10, Clinical COPD Questionnaire (CCQ) ≥1 and SGRQ ≥25 was moderate to very good. Best agreement was reached between CCQ and SGRQ (К = 0.838 or 0.851, p<0.001). Patients classified in mMRC GOLD A reported higher SGRQ scores, higher HADS-A and HADS-D scores compared to patients classified in CAT GOLD A or SGRQ GOLD A. Outcomes were comparable between the risk assessment groups. Conclusions: Choice of the symptom measure impacts GOLD groups more than choice of the exacerbation risk assessment. Health care professionals should be aware that patients are heterogeneous in terms of health status and symptoms of anxiety and depression based on the symptom measure used.

Entities:  

Keywords:  CAT; CCQ; COPD Assessment Test; GOLD; Global initiative for chronic Obstructive Lung Dis; SGRQ; St. George’s Respiratory Questionnaire; chronic obstructive pulmonary disease; clinical COPD questionnaire; copd

Year:  2014        PMID: 28848823      PMCID: PMC5556866          DOI: 10.15326/jcopdf.1.2.2014.0135

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  32 in total

1.  Impact of symptoms of anxiety and depression on COPD Assessment Test scores.

Authors:  Christina W Hilmarsen; Sarah Wilke; Harald Engan; Martijn A Spruit; Johan Rodenburg; Daisy J A Janssen; Sigurd Steinshamn; Paul W Jones; Emiel F M Wouters; Line Oldervoll; Frits M E Franssen
Journal:  Eur Respir J       Date:  2013-10-10       Impact factor: 16.671

Review 2.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 4.  FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts.

Authors:  Alvar Agusti; Suzanne Hurd; Paul Jones; Leonardo M Fabbri; Fernando Martinez; Claus Vogelmeier; Jørgen Vestbo; Robert Rodriguez-Roisin
Journal:  Eur Respir J       Date:  2013-05-03       Impact factor: 16.671

5.  Development and first validation of the COPD Assessment Test.

Authors:  P W Jones; G Harding; P Berry; I Wiklund; W-H Chen; N Kline Leidy
Journal:  Eur Respir J       Date:  2009-09       Impact factor: 16.671

6.  Global Initiative for Chronic Obstructive Lung Disease 2011 symptom/risk assessment in α1-antitrypsin deficiency.

Authors:  Anilkumar P Pillai; Alice M Turner; Robert A Stockley
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

7.  Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ).

Authors:  Ioanna G Tsiligianni; Thys van der Molen; Despoina Moraitaki; Ilaine Lopez; Janwillem W H Kocks; Konstantinos Karagiannis; Nikolaos Siafakas; Nikolaos Tzanakis
Journal:  BMC Pulm Med       Date:  2012-05-20       Impact factor: 3.317

8.  Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses.

Authors:  Sunmin Kim; Jisun Oh; Yu-Il Kim; Hee-Jung Ban; Yong-Soo Kwon; In-Jae Oh; Kyu-Sik Kim; Young-Chul Kim; Sung-Chul Lim
Journal:  BMC Pulm Med       Date:  2013-06-03       Impact factor: 3.317

9.  Usefulness of the COPD assessment test (CAT) in primary care.

Authors:  Arnulf Langhammer; Rupert Jones
Journal:  Prim Care Respir J       Date:  2013-03

10.  Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

Authors:  Alvar Agusti; Lisa D Edwards; Bartolomé Celli; William Macnee; Peter M A Calverley; Hana Müllerova; David A Lomas; Emiel Wouters; Per Bakke; Steve Rennard; Courtney Crim; Bruce E Miller; Harvey O Coxson; Julie C Yates; Ruth Tal-Singer; Jørgen Vestbo
Journal:  Eur Respir J       Date:  2013-06-13       Impact factor: 16.671

View more
  3 in total

1.  Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan.

Authors:  Keiji Oishi; Tsunahiko Hirano; Kazuki Hamada; Sho Uehara; Ryo Suetake; Yoshikazu Yamaji; Kosuke Ito; Maki Asami-Noyama; Nobutaka Edakuni; Kazuto Matsunaga
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-05

2.  How to Utilize CAT and mMRC Scores to Assess Symptom Status of Patients with COPD in Clinical Practice?

Authors:  Esra Ertan Yazar; Elif Yelda Niksarlioglu; Burcu Yigitbas; Mesut Bayraktaroglu
Journal:  Medeni Med J       Date:  2022-06-23

3.  Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores.

Authors:  Sarah Houben-Wilke; Daisy J A Janssen; Frits M E Franssen; Lowie E G W Vanfleteren; Emiel F M Wouters; Martijn A Spruit
Journal:  Health Qual Life Outcomes       Date:  2018-10-30       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.